β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris

Shakti Singh1,2, Ashley Barbarino1, Eman G Youssef1

  • 1Infectious Diseases & Immunology Hub, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA, USA.

NPJ Vaccines
|May 16, 2026
PubMed

Insights

A novel vaccine using beta-glucan chitosan particles (GCP) shows promise against multidrug-resistant Candida auris infections. GCP vaccination protected mice, reduced fungal burden, and offers a new strategy against this dangerous pathogen.

Area of Science:

  • Mycology
  • Immunology
  • Infectious Diseases

Background:

  • Multidrug-resistant Candida auris poses a significant threat, causing life-threatening infections with high mortality rates.
  • Limited treatment options exist due to widespread antifungal resistance.
  • Candida auris cell walls contain beta-glucan and conserved glycoproteins, presenting potential vaccine targets.

Purpose of the Study:

  • To evaluate beta-glucan chitosan particles (GCP) as a vaccine candidate against Candida auris.
  • To assess the humoral and cellular immune responses induced by GCP vaccination.
  • To determine the protective efficacy of GCP against disseminated C. auris infection in a mouse model.

Main Methods:

  • GCP were developed and used to vaccinate mice.
  • Humoral (IgG) and cellular (IFN-γ, IL-4, IL-17 producing T cells) immune responses were analyzed.
  • Vaccinated mice were challenged with C. auris, and survival, fungal burden, and abscesses were assessed.

Main Results:

  • GCP vaccination induced robust IgG antibody and T cell responses recognizing C. auris cell wall proteins.
  • Anti-GCP antibodies cross-reacted with C. auris isolates from multiple clades.
  • Vaccinated mice showed significantly improved survival (40% vs 0%), reduced fungal burden in organs, and fewer abscesses compared to controls.

Conclusions:

  • Beta-glucan chitosan particles (GCP) represent a promising vaccine candidate against multidrug-resistant Candida auris.
  • GCP vaccination elicits protective immune responses against disseminated C. auris infection.
  • This strategy offers a potential new therapeutic approach for combating C. auris infections.